Helena Laboratories
Private Company
Funding information not available
Overview
Helena Laboratories is a long-established, privately-held diagnostics company with a 60-year history, focusing on automated clinical laboratory instrumentation and reagents. Its flagship products are the SPIFE Nexus and V8 Nexus CE systems for high-throughput gel and capillary electrophoresis, primarily used for serum protein electrophoresis (SPE) and immunofixation (IFE) to monitor conditions like multiple myeloma. The company has a diversified portfolio spanning electrophoresis, hemostasis (Actalyke), point-of-care platelet function (Plateletworks), and fecal occult blood tests (FOBT), supported by a strong manufacturing base and global distribution network. It operates as a revenue-generating business with a direct sales and service model, leveraging its extensive patent portfolio and deep expertise in clinical protein separation.
Technology Platform
Automated gel and capillary electrophoresis systems (SPIFE Nexus, V8 Nexus CE), integrated Touch Series platform with sample handling and densitometry, point-of-care hemostasis and platelet function testing (Actalyke, Plateletworks).
Opportunities
Risk Factors
Competitive Landscape
Helena competes in the electrophoresis segment against companies like Sebia (a leader in protein electrophoresis), Thermo Fisher Scientific, and Bio-Rad. In hemostasis and point-of-care testing, it faces competitors such as Werfen, Roche, and Abbott. Its competitive advantage lies in deep specialization, a fully automated gel electrophoresis offering, integrated software, and a long-standing reputation in the clinical lab market.